As with any new breakthrough medicine, entering the healthcare system comes with a host of obstacles and potential barriers. In this episode, Adam Rutherford and guests break down the big changes needed within the global healthcare ecosystem to ensure that, once approved, the therapies we’re researching now, like gene therapy, reach the patients who need them. Featuring guests: Bert Bruce, Regional President, North America, Rare Disease, Pfizer Brenda Cooperstone, Senior Vice President, Chief Development Officer, Rare Disease, Pfizer Durhane Wong-Rieger, President & CEO at Canadian Organization for Rare Disorders Emily Crossley, Chief Executive Officer, Duchenne UK Erik Paulsen, Chair, Institute for Gene Therapies Karolina Hanslik, Senior Project Manager, EURORDIS Katherine Beaverson, Senior Director and Patient Advocacy Lead, Rare Disease Research Unit, Pfizer Nikhil Gadre, Senior Director, Global Commercial, Hemophilia Gene Therapy, Pfizer Suneet Varma, Global President, Rare Disease, Pfizer Tomislav Sokol, Member of European Parliament Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
